
The creation and continued development of antibiotics have revolutionized human health and disease for the past century. The emergence of antimicrobial resistance represents a major threat to human health, and practices that contribute to the development of this threat need to be addressed. Since the 1950s, antibiotics have been used in low doses to increase growth and decrease the feed requirement of animal-derived food sources. A consequence of this practice is the accelerated emergence of antimicrobial resistance that can influence human health through its distribution via animal food products. In the laboratory setting, sublethal doses of antibiotics promote the expansion of bacterial persister populations, a low energy, low metabolism phenotype characterized broadly by antibiotic tolerance. Furthermore, the induction of persister bacteria has been positively correlated with an increased emergence of antibiotic-resistant strains. This body of evidence suggests that the use of antibiotics in agriculture at subtherapeutic levels is actively catalyzing the emergence of antimicrobial-resistant bacteria through the expansion of bacterial persister populations, which is potentially leading to increased infections in humans and decreased antibiotic potency. There is an urgent need to address this debilitating effect on antibiotics and its influence on human health. In this review, we summarize the recent literature on the topic of emerging antimicrobial resistance and its association with bacterial persister populations.
Citation: Noah T Thompson, David A Kitzenberg, Daniel J Kao. Persister-mediated emergence of antimicrobial resistance in agriculture due to antibiotic growth promoters[J]. AIMS Microbiology, 2023, 9(4): 738-756. doi: 10.3934/microbiol.2023038
[1] | Mahdi Jalili . EEG-based functional brain networks: Hemispheric differences in males and females. Networks and Heterogeneous Media, 2015, 10(1): 223-232. doi: 10.3934/nhm.2015.10.223 |
[2] | Rosa M. Benito, Regino Criado, Juan C. Losada, Miguel Romance . Preface: "New trends, models and applications in complex and multiplex networks". Networks and Heterogeneous Media, 2015, 10(1): i-iii. doi: 10.3934/nhm.2015.10.1i |
[3] | Regino Criado, Rosa M. Benito, Miguel Romance, Juan C. Losada . Preface: Mesoscales and evolution in complex networks: Applications and related topics. Networks and Heterogeneous Media, 2012, 7(3): i-iii. doi: 10.3934/nhm.2012.7.3i |
[4] | Mirela Domijan, Markus Kirkilionis . Graph theory and qualitative analysis of reaction networks. Networks and Heterogeneous Media, 2008, 3(2): 295-322. doi: 10.3934/nhm.2008.3.295 |
[5] | M. D. König, Stefano Battiston, M. Napoletano, F. Schweitzer . On algebraic graph theory and the dynamics of innovation networks. Networks and Heterogeneous Media, 2008, 3(2): 201-219. doi: 10.3934/nhm.2008.3.201 |
[6] | Robert Carlson . Spectral theory for nonconservative transmission line networks. Networks and Heterogeneous Media, 2011, 6(2): 257-277. doi: 10.3934/nhm.2011.6.257 |
[7] | Jun Guo, Yanchao Shi, Yanzhao Cheng, Weihua Luo . Projective synchronization for quaternion-valued memristor-based neural networks under time-varying delays. Networks and Heterogeneous Media, 2024, 19(3): 1156-1181. doi: 10.3934/nhm.2024051 |
[8] | Jan Haskovec, Vybíral Jan . Robust network formation with biological applications. Networks and Heterogeneous Media, 2024, 19(2): 771-799. doi: 10.3934/nhm.2024035 |
[9] | Mahendra Piraveenan, Mikhail Prokopenko, Albert Y. Zomaya . On congruity of nodes and assortative information content in complex networks. Networks and Heterogeneous Media, 2012, 7(3): 441-461. doi: 10.3934/nhm.2012.7.441 |
[10] | Anirban Banerjee, Jürgen Jost . Spectral plot properties: Towards a qualitative classification of networks. Networks and Heterogeneous Media, 2008, 3(2): 395-411. doi: 10.3934/nhm.2008.3.395 |
The creation and continued development of antibiotics have revolutionized human health and disease for the past century. The emergence of antimicrobial resistance represents a major threat to human health, and practices that contribute to the development of this threat need to be addressed. Since the 1950s, antibiotics have been used in low doses to increase growth and decrease the feed requirement of animal-derived food sources. A consequence of this practice is the accelerated emergence of antimicrobial resistance that can influence human health through its distribution via animal food products. In the laboratory setting, sublethal doses of antibiotics promote the expansion of bacterial persister populations, a low energy, low metabolism phenotype characterized broadly by antibiotic tolerance. Furthermore, the induction of persister bacteria has been positively correlated with an increased emergence of antibiotic-resistant strains. This body of evidence suggests that the use of antibiotics in agriculture at subtherapeutic levels is actively catalyzing the emergence of antimicrobial-resistant bacteria through the expansion of bacterial persister populations, which is potentially leading to increased infections in humans and decreased antibiotic potency. There is an urgent need to address this debilitating effect on antibiotics and its influence on human health. In this review, we summarize the recent literature on the topic of emerging antimicrobial resistance and its association with bacterial persister populations.
Antibiotic-Free Feed;
Antibiotic Growth Promoter;
Antimicrobial Peptide;
Antimicrobial Resistance;
Conventional Feed;
Fluoroquinolone;
Guidance for Industry;
Minimum Duration for Killing;
Minimum Inhibitory Concentration;
non-Antibiotic Growth Promoter;
United States Food & Drug Administration;
Urinary Tract Infection
COVID-19 is an emerging acute infectious disease, which incubation period is 1–14 days, usually 3–7 days. COVID-19 generally have no obvious precursors, the infection will be after the Coronavirus disease early, some patients may also have no obvious symptoms, most common in patients with fever, dry cough, lack of power as the main performance, but beyond that, due to individual differences, the patient also can appear muscle pain, chest tightness, pharyngeal itching, runny nose. The lack of specificity, which can be seen in many diseases and is not unique to COVID-19, makes it difficult for patients to identify infection by symptoms themselves. Some immunity can be acquired after infection or after the cornavirus vaccine, but the duration is unclear.
The establishing and analyzing of mathematical models play an important role in the control and prevention for disease transmissing. McKendrick first proposed the PDE formulation for the age distribution of a population [1]. Ever since the research results by Kermack and McKendrick [2], Hoppensteadt [3], Iannalli [4] and Webb [5], age structure models have been widely used in the study of transmission dynamics of infectious diseases [6,7,8]. Recently, Bentout Soufiane et al. considered an alcoholism model for age structure and investigated the glabal behavior [9]. In December 2019, some medical institutions of Wuhan reported some cases of pneumonia of unknown cause. On 11 February 2020, the World Health Organization officially named the pneumonia contracted by the Novel Coronavirus as "COVID-19". Recently many scholars have studied on COVID-19, which all proposed and studied the dynamical model which has helped to control infectious diseases. Glenn Webb proposed a model of a COVID-19 epidemic which is developed to predict the effectiveness of vaccination [10]. B. Tang et al. proposed calculation of the basic reproduction number by virtue of mathematical modeling can help decide the potential and severity of an outbreak and provide critical information for identifying the type of disease interventions and intensity [11]. J. Jiao et al. presents an SEIR epidemic model with infectivity in incubation period and homestead-isolation on the susceptible [12]. Besides, deep learning frameworks [13] also can be used for prediction virus spread and a more reliable model incorporating more parameters input into a neural network based virus transmission predictor may be implemented.
McCluskey assumed that infected individuals can develop disease by either of two pathogenic machanism: fast progression or endogenous reactivation [14]. Generally, acute infectious diseases develop through four stages, among which the incubation period is very important, which refers to the period from pathogen invasion to the onset of clinical symptoms. Take COVID-19 for example which has a certain incubation period. According to current epidemiological statistics, the incubation period is about 1–14 days. Some patients will show symptoms on the day of infection or one or two days later, while some patients will have a longer incubation period of about two weeks. Consequently, it is necessary to consider the factors of fast and slow progress in infection modeling.
Besides, the treatment of disease is proportional due to medical resources. Capasso and Serill [15] introducing saturated incidence in the cholera epidemic model, describes the tingible into infected class average relationship g(I)=kI/(1+μ),k,μ>0, which said the disease infection ability, said a crowded or change on the influence of the individual, the increase in the number of infected people, easy to dye more vigilant, lead to easy dyeing behaviour change or when the disease is especially crowded in the environment may be unlimited effective contact.
Zunyou Wu who is the chief expert of epidemiology at the Chinese Center for Disease Control and Prevention, said there are three possible cases of re-positive symptoms for COVID-19: first, false negative or false positive nucleic acid test; second, the virus is active again; third, reinfection. Zijian Feng who is the deputy director of the Chinese Center for Disease Control and Prevention, said that the re-positive case caused continued transmission is rare and does not play a big role. Recently, some provinces in China have seen new cases of COVID-19 including asymptomatic patients. Therefore an infected individual ows into the exposed class after been treated but not becomes susceptible in our models. Inspired by the above discussions, we consider an SEI epidemic model which introduce the latent age, the nonlinear incidence of reactive unsaturated treatment and the saturation treatment function.
{dS(t)dt=Λ−βSI−μS,∂e(t,a)dt+∂e(t,a)da=−(μ+α(a))e(t,a),dI(t)dt=∫∞0α(a)e(t,a)da+(1−p)βSI−f(I)−(d+μ)I, | (2.1) |
for boundary and initial values conditions
e(t,0)=pβSI+f(I),S(0)=S0,e(0,a)=e0(a),I(0)=I0. | (2.2) |
where S(t),e(t,a) and I(t) respectively be the population sizes of susceptible, latent and infective classes. We assume that the population size is changeless. β represents susceptible people in contact with an infected person transmit rate, p represents susceptible people contact with an infected person enter slow propagation process called latent stage which denoted by e(t, a) where individuals are infected with disease but are not yet contagious, where a is called the age of latency progression, which is the duration of the incubation period. We denote E(t)=∫+∞0e(t,a)da as the latent individuals' total density. 1−p represents susceptible people and the onset of contact after rapid development for the onset of ratio, μ and d represent people natural mortality and mortality due to illness. f(x)=γx/(1+mx) represents the saturation treatment function where the γ is cure rate of the disease.
We define X=R+×L1+(0,+∞)×R+, equipped with the norm ‖(x1,x2,x3)‖X=|x1|+∫∞0x2(a)da+|x3|. The initial condition of system (2.1) belongs to the positive cone of X, then can be rewritten as x0=(S0,e0(⋅),I0)∈X. We can get a continuous semi-flow associated with system (2.1), that is, Θ:R+×X⟶X produced be system (2.1) adopts the following form, Θ(t,x0)=(S(t),e(t,⋅),I(t)),t≥0,x0∈X, with
∥Θ(t,x0)∥X=|(S(t)|+∫+∞0|e(t,⋅)|da+|I(t)|. | (2.3) |
For simplicity, let ε(s)=u+α(s),θ=∫∞0α(a)e−∫a0ε(τ)dτda,K0(a)=e−∫a0ε(τ)dτ. The second equation of system (2.1) is solved along t−a=constant
e(t,a)={(pβS(t−a)I(t−a)+γI(t−a)1+mI(t−a))K0(a),t>a≥0,e0(a−t)K0(a)K0(a−t),a≥t≥0, | (2.4) |
Let Ω={(S(t),e(t,⋅),I(t))∈X, S(t)+∫+∞0e(t,a)da+I(t)≤Λμ}. The interior of Ω is ˚Ω. we can easily verify the non-negative and positive invariance set of the system (2.1) with the help of article [5].
We note that if R0>1, Ω is the positive invariant set for Θ, and it attracts all solutions of the system (2.1) with non-negative initial conditions.
Firstly, there is a disease-free equilibrium point E0=(S0,0,0) in the system (2.1), where S0=Λμ, and we define the basic reproduction number of the system (2.1) as following
R0=pβΛθ+γμθ+(1−p)βΛ(γ+d+μ)μ |
and it is easily known that if R0>1, system (2.1) has an only positive endemic equilibrium point E∗(S∗,e∗(a),I∗), where
S∗=ΛβI∗+μ,e∗(a)=(pβS∗I∗+γI∗1+mI∗)e−∫a0ε(τ)dτ. |
Define space
X:=R3×L1((0,+∞),R),X0:=R2×0×L1((0,+∞),R),X+:=R3+×L1+((0,+∞),R), |
and X0+=X+⋂X0. Define operator T:D(T)⊂X→X,
T(SI(0e))=(−μ−(d+μ)(−e(0)−e′−(μ+α(a))e)) |
where D(T)=R×R×0×W1,1((0,+∞),R). Consider nonlinear mapping F:X0→X, for
F(SI(0e))=(Λ−βSI∫∞0α(a)e(t,a)da+(1−p)βSI−f(I)(pβSI+f(I)0L1)) |
define
U(t)=(S(t),I(t),(0e(t,⋅)))T |
Therefore systerm (2.1) can be rewritten as an abstract Canchy problem
dU(t)dt=TU(t)+F(U(t))t≥0,U(0)=u0∈X0+. | (2.5) |
Draw on the results in Magal [16] and Magal and Thiemel [17], there exists an uniquely deterministic semiflow {U(t)}t≥0 on X0+ which is bound dissipative and asymptotically smooth, and {U(t)}t≥0 has a global attractor T⊂X which attracts the bounded sets of X.
Theorem 2.1. If R0≤1, the disease-free equilibrium E0 is locally asymptotically stable.
Proof. Let x1(t)=S(t)−S0, x2(t)=e(t,a), x3(t)=I(t), linearizing the system (2.1) at E0, and considering the exponential solution x1(t)=x01eλt,x2(t,a)=x02eλt,x3(t)=x03eλt, we can derive
{(λ+μ)x01+βS0x03=0,dx02(a)da=−(λ+μ+α(a))x02(a),x02(0)=pβS0x03+γx03,λx03=∫∞0α(a)x02(a)da+(1−p)βS0x03−(μ+d+γ)x03. | (2.6) |
Integrating the second equation of system (2.6) from 0 to a, considering the boundary condition, deduces x02(a)=(pβS0x03+γx03)e−(λ+μ)a−∫a0α(s)ds. Substituting x02(a) into the fourth equation of system (2.6), solving it, we get the characteristic equation
H(λ)=−λ+∫∞0α(a)(γ+pβΛμ)e−(μ+λ)ae−∫a0α(τ)dτda+(1−p)βΛμ−(d+μ+γ). |
easily know H′(λ)<0 which implies that H′(λ) is a decreasing function, and
limλ→+∞H(λ)=−∞,limλ→−∞H(λ)=+∞,H(0)=(d+μ+γ)(R0−1). |
Let λ=x+yi is an arbitrary complex root of H(λ)=0, then
H(x+yi)=−x+∫∞0α(a)(γ+pβΛμ)e−(μ+x)ae−∫a0α(τ)dτcos(ya)da+(1−p)βΛμ−(d+μ+γ)−(iy+∫∞0α(a)(γ+pβΛμ)e−(μ+x)ae−∫a0α(τ)dτisin(ya)da)=0. |
be equivalent to
−x+∫∞0α(a)(γ+pβΛμ)e−(μ+x)ae−∫a0α(τ)dτcos(ya)da+(1−p)βΛμ−(d+μ+γ)=0,y+∫∞0α(a)(γ+pβΛμ)e−(μ+x)ae−∫a0α(τ)dτsin(ya)da=0. |
And because 0=−x+∫∞0α(a)(γ+pβΛμ)e−(μ+x)ae−∫a0α(τ)dτcos(ya)da+(1−p)βΛμ−(d+μ+γ)≤H(x) then 0=H(λ)≤H(x) which stands for x<λ∗, where λ∗ is the unique real root of H(λ)=0. Thus if and only if R0≤1, all the roots of system (2.6) have negative real part.
Theorem 2.2. If R0>1, the unique endemic equilibrium E∗ is locally asymptotically stable.
Proof. The perturbation variables are as follows
y1(t)=S(t)−S∗,y2(t,a)=e(t,a)−e∗(a),y3(t)=I(t)−I∗. |
Linearizing system (2.1) at E∗ and assuming the form of solution is as follows
y1(t)=y01eλt,y2(t,a)=y02(a)eλt,y3(t)=y03eλt, | (2.7) |
where y01,y02(a),y03 will be determined. we get
{0=(λ+βI∗+μ)y01+βS∗y03,dy02(a)da=−(λ+μ+α(a))y02(a),y02(0)=pβy01I∗+pβy03S∗+γ(1+mI∗)2y03,λy03=∫∞0α(a)y02(a)da+(1−p)β(y01I∗+y03S∗)−γ(1+mI∗)2y03−(d+μ)y03. | (2.8) |
By calculating, we can get the following eqution
[λ+γ(1+mI∗)2+(d+μ)−(1−p)βS∗]y03−(1−p)βI∗y01=pβI∗y01W(λ)+(pβS∗+γ(1+mI∗)2)y03W(λ), | (2.9) |
where W(λ)=∫∞0α(a)e−(λ+μ)a−∫∞0α(τ)dτda satisfies the following properties
W(0)=θ,limλ→−∞W(λ)=+∞,limλ→+∞W(λ)=∫∞0α(a)da. |
From the first equation of system (2.8) and the Eq (2.9), we obtain the following characteristic equation
(λ+μ+βI∗)(λ+μ+d)=(λ+μ+βI∗){(W(λ)−1)γ(1+mI∗)2+[(1−p)β+pβW(λ)]ΛβI∗+μ}−βΛβI∗+μ[(p−1)βI∗−pβI∗W(λ)] | (2.10) |
Note M is the right side of the Eq (2.10). Assuming λ>0, M satisfies the following inequality
∣M∣≤R0(λ+βI∗+μ+1)(γ+d+μ). | (2.11) |
which is equivalent to
h(λ)=λ2+Pλ+Q≤0. |
where
P=βI∗+2μ+d−R0(γ+d+μ),Q=(βI∗+μ)(d+μ)−R0(βI∗+μ+1)(γ+d+μ). |
Since λ>0, therefore
(βI∗+μ)(d+μ)(βI∗+μ+1)(γ+d+μ)>R0. |
Let A=(βI∗+μ)(d+μ)(βI∗+μ+1)(γ+d+μ), easily know A<1, i.e. R0<1 which is contradict with R0>1. then we can get λ<0.
Theorem 2.3. If R0>1, there exists ε>0, such that for each ∀y∈M0, limt→+∞infd(U(t)y,∂M0)≥ε.Furthermore, there exists a compact subset H0⊂M0 which is a global attractor for {U(t)}t≥0 in M0.
Proof. Define M0={(S,I,0,e)T∈X0+:T(t)=I+∫∞0e(a)da>0}, and ∂M0=X0+∖M0. Firstly, let (S0,I0,0,e0)∈M0, we can get T′(t)≥−max{d+μ,μ+αmax}T(t), where αmax=esssupa∈(0,∞)α(a), easily know U(t)M0⊂M0. Secondly, if (S0,I0,0,e0)∈∂M0, with the help of system (2.4), we know if t≥0, we get I(t)=0 and ∫∞0e(t,a)da→0, for t→+∞. Therefore U(t)∂M0⊂∂M0. Let (S0,I0,0,e0)∈∂M0, we get
{dI(t)dt=∫∞0α(a)e(t,a)da+(1−p)βSI−f(I)−(d+μ)I,∂e(t,a)dt+∂e(t,a)da=−(μ+α(a))e(t,a),e(t,0)=pβSI+f(I),I(0)=I0,e(0,a)=e0(a) |
Since S(t)≤S0 as t→+∞, we get I(t)≤˜I(t),e(t,a)≤˜e(t,a), where
{d˜I(t)dt=∫∞0α(a)˜e(t,a)da+(1−p)βS0˜I−γ˜I−(d+μ)˜I,∂˜e(t,a)dt+∂˜e(t,a)da=−(μ+α(a))˜e(t,a),˜e(t,0)=pβS0˜I+γ˜I,˜I(0)=˜I0,˜e(0,a)=˜e0(a) | (2.12) |
By the system (2.4), we have
˜e(t,a)={(pβS0˜I(t−a)+γ˜I(t−a))K0(a),t>a≥0,˜e0(a−t)K0(a)K0(a−t),a≥t≥0, | (2.13) |
where K0(a)=e−∫a0ε(τ)dτ. Substituting system (2.13) into system (2.12), we obtain
{d˜I(t)dt=T1+T2+(1−p)βS0˜I−γ˜I−(d+μ)˜I˜I(0)=0 | (2.14) |
where
T1=∫t0α(a)(pβS0˜I(t−a)+γ˜I(t−a))K0(a)da,T2=∫+∞tα(a)˜e0(a−t)K0(a)K0(a−t)da. |
It's simple to know that if T2=0, we get that system (2.14) has an only solution ˜I(t)=0. From the system (2.13), we can get ˜e(t,0)=0,t→+∞. Through comparison, we get (I(t),e(t,a))→(0,0) for t→+∞.
Since E0=(S0,0,0,0L1) is globally asymptotically stable in ∂M0, next we only need to proof that Ws(E0)⋂M0=Θ, where Ws(E0)={z∈X0+,limt→+∞U(t)z=E0}. Assume there exists z∈Ws(E0)⋂M0, it follows that there exists t0>0 such that I(t0)+∫∞0e(t0,a)da>0. Using the method in [18], we have e(t,a)>0 for (t,a)∈[0,∞)×[0,∞), I(t)>0 for t≥0. By means of the method of Braueretal [19], the following function is defined
H(a)=∫∞aα(s)e−∫saε(τ)dτds |
for ∀a>0, H(a)≥0, and H(0)=θ. Furthermore, for ∀a≥0,H′(a)=−α(a)+ε(a)H(a). Let
Φ(t)=I(t)+∫∞0H(a)e(t,a)da |
which satisfies
dΦ(t)dt=I(d+μ)1+mI((θp+1−p)βS(1+mI)+(θ−1)γ(d+μ)−1). |
If R0>1, there exists t0>0 such that Φ(t)≥Φ(t0) for all t≥t0. Since Φ(t0)>0, this prevents that (I(t),e(t,a))→(0,0L1,0L1), which is contradiction with S(t) converges to S0 and I(t) converges to 0, for t→∞. We get the semiflow {U(t)}t≥0 is uniformly persistent with respect to the pair (∂M0,M0). Besides, there exists a compact subset H0⊂M0 which is a global attractor for {U(t)}t≥0 in M0.
Theorem 2.4. Assume α(a) is an bounded function, if R0<1, the infection-free equilibrium E0 is globally asymptotically stable. Note ˉα=lima∈[0,+∞)supα(a).
Proof. Consider systems (2.1)–(2.4) we get
∫∞0α(a)e(t,a)da≤∫t0α(a)[pβS(t−a)I(t−a)+γI(t−a)]K0(a)da+ˉα∥e∥L1e−μt | (2.15) |
where ∥e∥L1=∫+∞0e0(a)da. Take the limit of both sides of the inequality (Eq 2.15), since S≤Λμ and limt→+∞e−μt=0, we get
limt→+∞sup∫∞0α(a)e(t,a)da≤∫+∞0α(a)pβΛμK0(a)dalimt→+∞supI(t)+∫∞0γα(a)K0(a)dalimt→+∞supI(t). | (2.16) |
With the help of Taylor's formula and the third equation of system (2.1), we get
dI(t)dt≤∫∞0α(a)e(t,a)da+(1−p)βIΛμ−(γ+d+μ)I. | (2.17) |
By solving inequality (Eq 2.17) and taking the limit of both sides, we can get
limt→+∞supI(t)≤R0limt→+∞supI(t) |
Therefore, when R0<1, limt→+∞supI(t)=0. By using inequality (Eq 2.16) and system (2.1) respectively, we get limt→+∞supe(t,a)=0 and limt→+∞supS(t)=Λμ. Therefore, if R0<1, the disease-free equilibrium point E0 is global attraction. Further, with the help of Theorem 2.1, we have the disease-free equilibrium point is global asymptotically stable.
Theorem 2.5. If R0>1, the unique endemic equilibrium E∗ is globally asymptotically stable.
Proof. The Lyapunov functional V∗(t) is constructed
V∗(t)=WS+We+WI, | (2.18) |
where
WS(t)=(1−p)S∗g(SS∗),We(t)=∫∞0W(a)e∗(a)g(e(t,a)e∗(a))da,WI(t)=I∗g(II∗). |
for W(a)=∫+∞aα(s)e−∫sa(μ+α(τ))dτ,g(x)=−1+x−lnx, de∗(a)da=−ε(a)e∗(a). Calculating the derivative of the V∗(t) along with the solutions of system (2.18), yields
dV∗(t)dt=(1−p)μS∗(2−SS∗−S∗S)+(1−p)βS∗I∗(1−S∗S−SIS∗I∗+II∗)−W(a)e∗(a)g(e(t,a)e∗(a))|∞+θe∗(0)g(e(t,0)e∗(0))−∫∞0α(a)e∗(a)g(e(t,a)e∗(a))+∫∞0α(a)e∗(a)(1−II∗−I∗e(t,a)Ie∗(a)+e(t,a)e∗(a))da+(1−p)βS∗I∗(1−S∗S+SIS∗I∗−II∗)=(1−p)μS∗(2−SS∗−S∗S)+(1−p)βS∗I∗(2−S∗S−SS∗)−W(a)e∗(a)g(e(t,a)e∗(a))|∞+∫∞0α(a)e∗(a)(1−II∗−I∗e(t,a)Ie∗(a)+e(t,a)e∗(a)+1−e(t,a)e∗(a)+lne(t,a)e∗(a))da+θe∗(0)g(e(t,0)e∗(0))=(1−p)μS∗(2−SS∗−S∗S)+(1−p)βS∗I∗(2−S∗S−SS∗)−W(a)e∗(a)g(e(t,a)e∗(a))|∞−∫∞0α(a)e∗(a)(g(II∗)+g(I∗e(t,a)Ie∗(a))da+θe∗(0)g(e(t,0)e∗(0)) |
if II∗>1 and S∗S>1, or 0<II∗<1 and 0<S∗S<1, we have
θe∗(0)g(e(t,0)e∗(0))=∫∞0α(a)e∗(a)g(e(t,0)e∗(0))≤∫∞0α(a)e∗(a)g(II∗)da |
Hence,
dV∗(t)dt==(1−p)μS∗(2−SS∗−S∗S)+(1−p)βS∗I∗(2−S∗S−SS∗)−W(a)e∗(a)g(e(t,a)e∗(a))|∞−∫∞0α(a)e∗(a)(g(II∗)+g(I∗e(t,a)Ie∗(a))da+∫∞0α(a)e∗(a)g(II∗)da=(1−p)μS∗(2−SS∗−S∗S)+(1−p)βS∗I∗(2−S∗S−SS∗)−W(a)e∗(a)g(e(t,a)e∗(a))|∞−∫∞0α(a)e∗(a)g(I∗e(t,a)Ie∗(a))da |
For g(x)≥0,x∈R, therefore dV∗(t)dt≤0 is always true, furthermore the strict equality holds if and only if S=S∗,e(t,a)=e∗(a),I=I∗. Therefore when R0>1 the endemic equilibrium E∗ is globally asymptotically stable.
In the work, an age structure epidemic SEI model with fast and slow progression is considered. The basic reproduction number R0 is obtained as R0=pβΛθ+γμθ+(1−p)βΛ(γ+d+μ)μ. We have proved the globally asymptotically stable for disease-free and endemic equilibrium respectively. In the following, we also give some numerical simulations to illustrate the global stability. Let Λ=1;β=0.055;γ=0.7;μ=0.063;d=0.04;p=0.8;m=0.02;S(0)=30,e(0,a)=6e−0.4a,I(0)=10. and
α(a)={0.4,a≥τ0,τ≥a≥0. |
In Figure 1, we choose τ=12, then R0<1, it can be seen that E0 is globally asymptotically stable. While in Figure 2, we choose τ=1, then R0>1, it can be seen that E∗ is globally asymptotically stable. The figures show the series of S(t) and I(t) which converge to their equilibrium values, in addition the age distribution of e(t,a).
COVID-19 has spread rapidly around the world since 2020 with a high fatality rate. Today the epidemic in some countries is still unable to be effectively controlled, and social and economic life has been greatly disrupted. COVID-19 trend prediction has become a major research focus. Current trend prediction methods include epidemic disease prediction model, COVID-19 trend prediction model based on deep learning, etc. These models have effectively assisted medical experts and scientific research institutions to efficiently predict COVID-19. The countermeasures and suggestions for strengthening epidemic prevention and control are put forward, which have a good guiding role for accurate epidemic prevention and control.
The large-scale epidemic of COVID-19 in China has basically ended, but there are still occasional imported cases or local outbreaks caused by cold chain pollution which prevention and control enters a new phase of normalization. Since the outbreak of COVID-19, a large number of researchers have conducted extensive studies on infectious disease dynamics and prevention and control measures through various models and data analysis methods. Many scholars have built traditional dynamics models based on warehouses to explore the development trend of COVID-19 and provide scientific basis for epidemic prevention and control.
According to transmission characteristics of infectious diseases, the paper proposed the methods of fast and slow transmission, which more effectively reveals the transmission mechanism for infectious diseases. The global asymptotic stability of the system has analyzed with the help of the principle of dynamics, and abtained the threshold of infectious disease control. The greater the rate of slow progression of an infectious disease, the fewer the threshold results. The world is now being vaccinated which cannot provide lifelong immunity, but can reduce the mortality of those infected. By vaccinating, the rate of patients entering slow progression increases and the threshold is correspondingly reduced. Therefore, vaccination can effectively control the transmission of Coronavirus.
This research is supported by Guizhou Province Science and Technology Support Plan Project ([2020]4Y167), the National Natural Science Foundation of China (N0.12001417), Doctoral Foundation of Guizhou Education University (2018BS001), First-class University Construction Project of Guizhou Education University ([2019]35).
The authors declare there is no conflict of interest.
[1] |
Hutchings MI, Truman AW, Wilkinson B (2019) Antibiotics: past, present and future. Curr Opin Microbiol 51: 72-80. https://doi.org/10.1016/j.mib.2019.10.008 ![]() |
[2] |
Van Boeckel TP, Pires J, Silvester R, et al. (2019) Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science 365. https://doi.org/10.1126/science.aaw1944 ![]() |
[3] | Tiseo K, Huber L, Gilbert M, et al. (2020) Global trends in antimicrobial use in food animals from 2017 to 2030. Antibiotics (Basel) 9. https://doi.org/10.3390/antibiotics9120918 |
[4] |
Klein EY, Tseng KK, Pant S, et al. (2019) Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ Glob Health 4: e001315. https://doi.org/10.1136/bmjgh-2018-001315 ![]() |
[5] |
Van den Bergh B, Fauvart M, Michiels J (2017) Formation, physiology, ecology, evolution and clinical importance of bacterial persisters. FEMS Microbiol Rev 41: 219-251. https://doi.org/10.1093/femsre/fux001 ![]() |
[6] |
De Briyne N, Atkinson J, Pokludova L, et al. (2014) Antibiotics used most commonly to treat animals in Europe. Vet Rec 175. https://doi.org/10.1136/vr.102462 ![]() |
[7] |
Manyi-Loh C, Mamphweli S, Meyer E, et al. (2018) Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules 23. https://doi.org/10.3390/molecules23040795 ![]() |
[8] |
Antimicrobial Resistance C (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399: 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0 ![]() |
[9] |
Blair JM, Webber MA, Baylay AJ, et al. (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13: 42-51. https://doi.org/10.1038/nrmicro3380 ![]() |
[10] |
Lerminiaux NA, Cameron ADS (2019) Horizontal transfer of antibiotic resistance genes in clinical environments. Can J Microbiol 65: 34-44. https://doi.org/10.1139/cjm-2018-0275 ![]() |
[11] |
Levin-Reisman I, Ronin I, Gefen O, et al. (2017) Antibiotic tolerance facilitates the evolution of resistance. Science 355: 826-830. https://doi.org/10.1126/science.aaj2191 ![]() |
[12] |
Levin-Reisman I, Brauner A, Ronin I, et al. (2019) Epistasis between antibiotic tolerance, persistence, and resistance mutations. Proc Natl Acad Sci USA 116: 14734-14739. https://doi.org/10.1073/pnas.1906169116 ![]() |
[13] |
Windels EM, Michiels JE, Van den Bergh B, et al. (2019) Antibiotics: combatting tolerance to stop resistance. Mbio 10: e02095-19. https://doi.org/10.1128/mBio.02095-19 ![]() |
[14] |
Windels EM, Michiels JE, Fauvart M, et al. (2019) Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates. Isme J 13: 1239-1251. https://doi.org/10.1038/s41396-019-0344-9 ![]() |
[15] |
Bigger JW (1944) The bactericidal action of penicillin on staphylococcus pyogenes. Ir J Med Sci 19: 553-568. https://doi.org/10.1007/BF02948386 ![]() |
[16] |
Balaban NQ, Merrin J, Chait R, et al. (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622-1625. https://doi.org/10.1126/science.1099390 ![]() |
[17] |
Wilmaerts D, Windels EM, Verstraeten N, et al. (2019) General mechanisms leading to persister formation and awakening. Trends Genet 35: 401-411. https://doi.org/10.1016/j.tig.2019.03.007 ![]() |
[18] |
Moore PR, Evenson A, et al. (1946) Use of sulfasuxidine, streptothricin, and streptomycin in nutritional studies with the chick. J Biol Chem 165: 437-441. https://doi.org/10.1016/S0021-9258(17)41154-9 ![]() |
[19] |
Chattopadhyay MK (2014) Use of antibiotics as feed additives: a burning question. Front Microbiol 5: 334. https://doi.org/10.3389/fmicb.2014.00334 ![]() |
[20] |
Hosain MZ, Kabir SML, Kamal MM (2021) Antimicrobial uses for livestock production in developing countries. Vet World 14: 210-221. https://doi.org/10.14202/vetworld.2021.210-221 ![]() |
[21] |
Martin MJ, Thottathil SE, Newman TB (2015) Antibiotics overuse in animal agriculture: a call to action for health care providers. Am J Public Health 105: 2409-2410. https://doi.org/10.2105/AJPH.2015.302870 ![]() |
[22] |
Gaskins HR, Collier CT, Anderson DB (2002) Antibiotics as growth promotants: Mode of action. Anim Biotechnol 13: 29-42. https://doi.org/10.1081/ABIO-120005768 ![]() |
[23] |
Niewold TA (2007) The nonantibiotic anti-inflammatory effect of antimicrobial growth promoters, the real mode of action? A hypothesis. Poult Sci 86: 605-609. https://doi.org/10.1093/ps/86.4.605 ![]() |
[24] |
Coates ME, Fuller R, Harrison GF, et al. (1963) A comparision of the growth of chicks in the Gustafsson germ-free apparatus and in a conventional environment, with and without dietary supplements of penicillin. Br J Nutr 17: 141-150. https://doi.org/10.1079/BJN19630015 ![]() |
[25] |
Broom LJ (2017) The sub-inhibitory theory for antibiotic growth promoters. Poult Sci 96: 3104-3108. https://doi.org/10.3382/ps/pex114 ![]() |
[26] |
Visek WJ (1978) The mode of growth promotion by antibiotics. J Anim Sci 46: 1447-1469. https://doi.org/10.2527/jas1978.4651447x ![]() |
[27] | Jukes TH, Williams WL (1953) Nutritional effects of antibiotics. Pharmacol Rev 5: 381-420. |
[28] |
Kim HB, Borewicz K, White BA, et al. (2012) Microbial shifts in the swine distal gut in response to the treatment with antimicrobial growth promoter, tylosin. Proc Natl Acad Sci USA 109: 15485-15490. https://doi.org/10.1073/pnas.1205147109 ![]() |
[29] |
Plata G, Baxter NT, Susanti D, et al. (2022) Growth promotion and antibiotic induced metabolic shifts in the chicken gut microbiome. Commun Biol 5: 293. https://doi.org/10.1038/s42003-022-03239-6 ![]() |
[30] |
Robinson K, Becker S, Xiao Y, et al. (2019) Differential impact of subtherapeutic antibiotics and ionophores on intestinal microbiota of broilers. Microorganisms 7: 282. https://doi.org/10.3390/microorganisms7090282 ![]() |
[31] |
Torok VA, Allison GE, Percy NJ, et al. (2011) Influence of antimicrobial feed additives on broiler commensal posthatch gut microbiota development and performance. Appl Environ Microbiol 77: 3380-3390. https://doi.org/10.1128/AEM.02300-10 ![]() |
[32] |
Agunos A, Gow SP, Leger DF, et al. (2019) Antimicrobial use and antimicrobial resistance indicators-integration of farm-level surveillance data from broiler chickens and Turkeys in British Columbia, Canada. Front Vet Sci 6: 131. https://doi.org/10.3389/fvets.2019.00131 ![]() |
[33] | (2017) ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals: Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) Report. EFSA J 15: e04872. https://doi.org/10.2903/j.efsa.2017.4872 |
[34] |
Hiki M, Kawanishi M, Abo H, et al. (2015) Decreased resistance to broad-spectrum cephalosporin in escherichia coli from healthy broilers at farms in Japan after voluntary withdrawal of ceftiofur. Foodborne Pathog Dis 12: 639-643. https://doi.org/10.1089/fpd.2015.1960 ![]() |
[35] |
Sundsfjord A, Simonsen GS, Courvalin P (2001) Human infections caused by glycopeptide-resistant Enterococcus spp: are they a zoonosis?. Clin Microbiol Infect 7: 16-33. https://doi.org/10.1046/j.1469-0691.2001.00055.x ![]() |
[36] |
Aarestrup FM, Kruse H, Tast E, et al. (2000) Associations between the use of antimicrobial agents for growth promotion and the occurrence of resistance among Enterococcus faecium from broilers and pigs in Denmark, Finland, and Norway. Microb Drug Resist 6: 63-70. https://doi.org/10.1089/mdr.2000.6.63 ![]() |
[37] |
Kumar K, Gupta SC, Chander Y, et al. (2005) Antibiotic use in agriculture and its impact on the terrestrial environment. Adv Agron 87: 1-54. https://doi.org/10.1016/S0065-2113(05)87001-4 ![]() |
[38] |
Sarmah AK, Meyer MT, Boxall ABA (2006) A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. Chemosphere 65: 725-759. https://doi.org/10.1016/j.chemosphere.2006.03.026 ![]() |
[39] |
Meyerhoff A, Albrecht R, Meyer JM, et al. (2004) US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin Infect Dis 39: 303-308. https://doi.org/10.1086/421491 ![]() |
[40] |
Chantziaras I, Boyen F, Callens B, et al. (2014) Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. J Antimicrob Chem 69: 827-834. https://doi.org/10.1093/jac/dkt443 ![]() |
[41] |
Norstrom M, Hofshagen M, Stavnes T, et al. (2006) Antimicrobial resistance in Campylobacter jejuni from humans and broilers in Norway. Epidemiol Infect 134: 127-130. https://doi.org/10.1017/S0950268805004814 ![]() |
[42] |
de Been M, Lanza VF, de Toro M, et al. (2014) Dissemination of cephalosporin resistance genes between Escherichia coli strains from farm animals and humans by specific plasmid lineages. PLoS Genet 10: e1004776. https://doi.org/10.1371/journal.pgen.1004776 ![]() |
[43] |
Woolhouse M, Ward M, van Bunnik B, et al. (2015) Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci 370: 20140083. https://doi.org/10.1098/rstb.2014.0083 ![]() |
[44] |
Muloi D, Ward MJ, Pedersen AB, et al. (2018) Are food animals responsible for transfer of antimicrobial-resistant escherichia coli or their resistance determinants to human populations? a systematic review. Foodborne Pathog Dis 15: 467-474. https://doi.org/10.1089/fpd.2017.2411 ![]() |
[45] |
Gutierrez A, Jain S, Bhargava P, et al. (2017) Understanding and sensitizing density-dependent persistence to quinolone antibiotics. Molecular Cell 68: 1147-1154 e1143. https://doi.org/10.1016/j.molcel.2017.11.012 ![]() |
[46] |
Helaine S, Kugelberg E (2014) Bacterial persisters: formation, eradication, and experimental systems. Trends Microbiol 22: 417-424. https://doi.org/10.1016/j.tim.2014.03.008 ![]() |
[47] |
Stapels DAC, Hill PWS, Westermann AJ, et al. (2018) Salmonella persisters undermine host immune defenses during antibiotic treatment. Science 362: 1156-1160. https://doi.org/10.1126/science.aat7148 ![]() |
[48] |
Balaban NQ, Helaine S, Lewis K, et al. (2019) Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol 17: 441-448. https://doi.org/10.1038/s41579-019-0196-3 ![]() |
[49] |
Brauner A, Fridman O, Gefen O, et al. (2016) Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol 14: 320-330. https://doi.org/10.1038/nrmicro.2016.34 ![]() |
[50] |
Ronneau S, Hill PW, Helaine S (2021) Antibiotic persistence and tolerance: not just one and the same. Curr Opin Microbiol 64: 76-81. https://doi.org/10.1016/j.mib.2021.09.017 ![]() |
[51] |
Barrett TC, Mok WWK, Murawski AM, et al. (2019) Enhanced antibiotic resistance development from fluoroquinolone persisters after a single exposure to antibiotic. Nat Commun 10: 1177. https://doi.org/10.1038/s41467-019-09058-4 ![]() |
[52] |
Allison KR, Brynildsen MP, Collins JJ (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216-220. https://doi.org/10.1038/nature10069 ![]() |
[53] |
Pontes MH, Groisman EA (2019) Slow growth determines nonheritable antibiotic resistance in Salmonella enterica. Sci Signal 12. https://doi.org/10.1126/scisignal.aax3938 ![]() |
[54] |
Fridman O, Goldberg A, Ronin I, et al. (2014) Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature 513: 418-421. https://doi.org/10.1038/nature13469 ![]() |
[55] |
Rowe SE, Wagner NJ, Li L, et al. (2020) Reactive oxygen species induce antibiotic tolerance during systemic Staphylococcus aureus infection. Nat Microbiol 5: 282-290. https://doi.org/10.1038/s41564-019-0627-y ![]() |
[56] | Tuomanen E, Cozens R, Tosch W, et al. (1986) The rate of killing of escherichia-coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial-growth. J Gen Microbiol 132: 1297-1304. https://doi.org/10.1099/00221287-132-5-1297 |
[57] |
Amato SM, Orman MA, Brynildsen MP (2013) Metabolic control of persister formation in Escherichia coli. Molecular Cell 50: 475-487. https://doi.org/10.1016/j.molcel.2013.04.002 ![]() |
[58] |
Helaine S, Cheverton AM, Watson KG, et al. (2014) Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science 343: 204-208. https://doi.org/10.1126/science.1244705 ![]() |
[59] |
Hill PWS, Moldoveanu AL, Sargen M, et al. (2021) The vulnerable versatility of Salmonella antibiotic persisters during infection. Cell Host Microbe 29: 1757-1773. https://doi.org/10.1016/j.chom.2021.10.002 ![]() |
[60] |
Korch SB, Henderson TA, Hill TM (2003) Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis. Mol Microbiol 50: 1199-1213. https://doi.org/10.1046/j.1365-2958.2003.03779.x ![]() |
[61] |
Moyed HS, Bertrand KP (1983) Hipa, a newly recognized gene of escherichia-coli k-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 155: 768-775. https://doi.org/10.1128/jb.155.2.768-775.1983 ![]() |
[62] |
Wilmaerts D, Bayoumi M, Dewachter L, et al. (2018) The persistence-inducing toxin HokB forms dynamic pores that cause atp leakage. Mbio 9. https://doi.org/10.1128/mBio.00744-18 ![]() |
[63] |
Zalis EA, Nuxoll AS, Manuse S, et al. (2019) Stochastic variation in expression of the tricarboxylic acid cycle produces persister cells. Mbio 10. https://doi.org/10.1128/mBio.01930-19 ![]() |
[64] |
Verstraeten N, Knapen WJ, Kint CI, et al. (2015) Obg and membrane depolarization are part of a microbial bet-hedging strategy that leads to antibiotic tolerance. Mol Cell 59: 9-21. https://doi.org/10.1016/j.molcel.2015.05.011 ![]() |
[65] |
Allison KR, Brynildsen MP, Collins JJ (2011) Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol 14: 593-598. https://doi.org/10.1016/j.mib.2011.09.002 ![]() |
[66] |
Conlon BP (2014) Staphylococcus aureus chronic and relapsing infections: Evidence of a role for persister cells An investigation of persister cells, their formation and their role in S. aureus disease. Bioessays 36: 991-996. https://doi.org/10.1002/bies.201400080 ![]() |
[67] |
Lewis K (2010) Persister cells. Annu Rev Microbiol 64: 357-372. https://doi.org/10.1146/annurev.micro.112408.134306 ![]() |
[68] |
Bakkeren E, Huisman JS, Fattinger SA, et al. (2019) Salmonella persisters promote the spread of antibiotic resistance plasmids in the gut. Nature 573: 276-280. https://doi.org/10.1038/s41586-019-1521-8 ![]() |
[69] |
Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417-433. https://doi.org/10.1128/MMBR.00016-10 ![]() |
[70] |
Huddleston JR (2014) Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes. Infect Drug Resist 7: 167-176. https://doi.org/10.2147/IDR.S48820 ![]() |
[71] | Wang HQ, Feng MY, Anwar TM, et al. (2023) Change in antimicrobial susceptibility of Listeria spp. in response to stress conditions. Front Sustainable Food Systems 7. https://doi.org/10.3389/fsufs.2023.1179835 |
[72] | Wu RA, Feng JS, Yue M, et al. (2023) Overuse of food-grade disinfectants threatens a global spread of antimicrobial-resistant bacteria. Crit Rev Food Sci Nutr . https://doi.org/10.1080/10408398.2023.2176814 |
[73] |
Cohen NR, Lobritz MA, Collins JJ (2013) Microbial persistence and the road to drug resistance. Cell Host Microbe 13: 632-642. https://doi.org/10.1016/j.chom.2013.05.009 ![]() |
[74] |
Douafer H, Andrieu V, Phanstiel O, et al. (2019) Antibiotic adjuvants: make antibiotics great again!. J Medl Chem 62: 8665-8681. https://doi.org/10.1021/acs.jmedchem.8b01781 ![]() |
[75] |
Kitzenberg DA, Lee JS, Mills KB, et al. (2022) Adenosine awakens metabolism to enhance growth-independent killing of tolerant and persister bacteria across multiple classes of antibiotics. Mbio 13. https://doi.org/10.1128/mbio.00480-22 ![]() |
[76] |
Meylan S, Andrews IW, Collins JJ (2018) Targeting antibiotic tolerance, pathogen by pathogen. Cell 172: 1228-1238. https://doi.org/10.1016/j.cell.2018.01.037 ![]() |
[77] |
Wright GD (2016) Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol 24: 862-871. https://doi.org/10.1016/j.tim.2016.06.009 ![]() |
[78] |
Bengtsson-Palme J, Kristiansson E, Larsson DGJ (2018) Environmental factors influencing the development and spread of antibiotic resistance. Fems Microbiol Rev 42: 68-80. https://doi.org/10.1093/femsre/fux053 ![]() |
[79] |
Blair JMA, Webber MA, Baylay AJ, et al. (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13: 42-51. https://doi.org/10.1038/nrmicro3380 ![]() |
[80] |
Darby EM, Trampari E, Siasat P, et al. (2023) Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol 21: 280-295. https://doi.org/10.1038/s41579-022-00820-y ![]() |
[81] |
Andersson DI, Hughes D (2014) Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 12: 465-478. https://doi.org/10.1038/nrmicro3270 ![]() |
[82] |
Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine 10: S122-S129. https://doi.org/10.1038/nm1145 ![]() |
[83] | Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. P T 40: 277-283. |
[84] |
Vega NM, Allison KR, Khalil AS, et al. (2012) Signaling-mediated bacterial persister formation. Nat Chem Biol 8: 431-433. https://doi.org/10.1038/nchembio.915 ![]() |
[85] | Reeks BY, Champlin FR, Paulsen DB, et al. (2005) Effects of sub-minimum inhibitory concentration antibiotic levels and temperature on growth kinetics and outer membrane protein expression in Mannheimia haemolytica and Haemophilus somnus. Can J Vet Res 69: 1-10. |
[86] |
Walsh SI, Peters DS, Smith PA, et al. (2019) Inhibition of protein secretion in escherichia coli and sub-mic effects of arylomycin antibiotics. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.01253-18 ![]() |
[87] | MedlinePlus (n.d.) Tetracycline: Medlineplus drug information. Available from https://medlineplus.gov/druginfo/meds/a682098.html. |
[88] | Pandey N, Cascella M Beta lactam antibiotics (2022). Available from https://www.ncbi.nlm.nih.gov/books/NBK545311/. |
[89] | Yan A, Bryant EE Quinolones (2023). Available from https://www.ncbi.nlm.nih.gov/books/NBK557777/. |
[90] |
Cowieson AJ, Kluenter AM (2019) Contribution of exogenous enzymes to potentiate the removal of antibiotic growth promoters in poultry production. Anim Feed Sci Technol 250: 81-92. https://doi.org/10.1016/j.anifeedsci.2018.04.026 ![]() |
[91] |
Seal BS, Lillehoj HS, Donovan DM, et al. (2013) Alternatives to antibiotics: a symposium on the challenges and solutions for animal production. Anim Health Res Rev 14: 78-87. https://doi.org/10.1017/S1466252313000030 ![]() |
[92] | Grassi L, Di Luca M, Maisetta G, et al. (2017) Generation of persister cells of pseudomonas aeruginosa and staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents. Front Microbiol 8. https://doi.org/10.3389/fmicb.2017.01917 |
[93] |
Hammerum AM, Heuer OE, Lester CH, et al. (2007) Comment on: withdrawal of growth-promoting antibiotics in Europe and its effects in relation to human health. Int J Antimicrob Agents 30: 466-468. https://doi.org/10.1016/j.ijantimicag.2007.07.012 ![]() |
[94] |
Phillips I (2007) Withdrawal of growth-promoting antibiotics in Europe and its effects in relation to human health. Int J Antimicrob Agents 30: 101-107. https://doi.org/10.1016/j.ijantimicag.2007.02.018 ![]() |
[95] |
Bywater RJ (2005) Identification and surveillance of antimicrobial resistance dissemination in animal production. Poult Sci 84: 644-648. https://doi.org/10.1093/ps/84.4.644 ![]() |
[96] |
Casewell M, Friis C, Marco E, et al. (2003) The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. J Antimicrob Chemother 52: 159-161. https://doi.org/10.1093/jac/dkg313 ![]() |
[97] |
Acar J, Casewell M, Freeman J, et al. (2000) Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making. Clin Microbiol Infect 6: 477-482. https://doi.org/10.1046/j.1469-0691.2000.00128.x ![]() |
[98] | Rahman MRT, Fliss I, Biron E (2022) Insights in the development and uses of alternatives to antibiotic growth promoters in poultry and swine production. Antibiotics (Basel) 11. https://doi.org/10.3390/antibiotics11060766 |
[99] | U.S. Food & Drug Administration CfVMCVM GFI #213 new animal drugs and new animal drug combination products administered in or on medicated feed or drinking water of food-producing animals: recommendations for drug sponsors for voluntarily aligning product use conditions with GFI #209 (2013). Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-or-medicated-feed |
[100] | U.S. Food & Drug Administration CfVM2021 summary report on antimicrobials sold or distributed for use in food-producing animals (2022). Available from https://www.fda.gov/media/163739/download?attachment |
[101] |
Li Y, Ed-Dra A, Tang B, et al. (2022) Higher tolerance of predominant Salmonella serovars circulating in the antibiotic-free feed farms to environmental stresses. J Hazard Mater 438: 129476. https://doi.org/10.1016/j.jhazmat.2022.129476 ![]() |
1. | Linze Qian, Xianliang Ge, Zhao Feng, Sujie Wang, Jingjia Yuan, Yunxian Pan, Hongqi Shi, Jie Xu, Yu Sun, Brain Network Reorganization During Visual Search Task Revealed by a Network Analysis of Fixation-Related Potential, 2023, 31, 1534-4320, 1219, 10.1109/TNSRE.2023.3242771 | |
2. | Ricardo Bruña, Fernando Maestú, David López-Sanz, Anto Bagic, Ann D. Cohen, Yue-Fang Chang, Yu Cheng, Jack Doman, Ted Huppert, Tae Kim, Rebecca E. Roush, Beth E. Snitz, James T. Becker, Sex Differences in Magnetoencephalography-Identified Functional Connectivity in the Human Connectome Project Connectomics of Brain Aging and Dementia Cohort, 2022, 12, 2158-0014, 561, 10.1089/brain.2021.0059 | |
3. | F. Miraglia, F. Vecchio, P. Bramanti, P.M. Rossini, Small-worldness characteristics and its gender relation in specific hemispheric networks, 2015, 310, 03064522, 1, 10.1016/j.neuroscience.2015.09.028 | |
4. | Monika Lewandowska, Krzysztof Tołpa, Jacek Rogala, Tomasz Piotrowski, Joanna Dreszer, Multivariate multiscale entropy (mMSE) as a tool for understanding the resting-state EEG signal dynamics: the spatial distribution and sex/gender-related differences, 2023, 19, 1744-9081, 10.1186/s12993-023-00218-7 | |
5. | Yingying Zhou, Yicheng Long, Sex differences in human brain networks in normal and psychiatric populations from the perspective of small-world properties, 2024, 15, 1664-0640, 10.3389/fpsyt.2024.1456714 |